The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

about

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

Item

http://www.wikidata.org/entity/Q41078536

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

@en

type

Item

label

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

@en

prefLabel

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

@en

P1476

The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

@en

P2093

Brooks D Cash

http://www.w3.org/2001/XMLSchema#string

Sherry Levio

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date

Rifaximin therapy for patients with irritable bowel syndrome without constipation

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Guidelines on the irritable bowel syndrome: mechanisms and practical management.

The epidemiology of irritable bowel syndrome in North America: a systematic review.

Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.

P304

715-725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X17721152

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28932272

http://www.w3.org/2001/XMLSchema#string

P921

Afọ ọsịsa

P932

5598810

http://www.w3.org/2001/XMLSchema#string